Working… Menu

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02592577
Recruitment Status : Recruiting
First Posted : October 30, 2015
Last Update Posted : February 6, 2019
Information provided by (Responsible Party):

Brief Summary:

This first time in human study is intended for men and women at least 18 years of age who have advanced lung cancer which has grown or returned after being treated. In particular, it is a study for subjects who have a blood test positive for HLA-A*02:01 and/or HLA-A*02:06 and a tumor test positive for MAGE A10 protein expression (protein or gene). This trial is a dose escalation trial that will evaluate 3 doses of transduced cells administered after a lymphodepleting chemotherapy regimen using a 3+3 dose escalation design .The study will take the subject's T cells, which are a natural type of immune cell in the blood, and send them to a laboratory to be modified. The changed T cells used in this study will be the subject's own T cells that have been genetically changed with the aim of attacking and destroying cancer cells.

When the MAGE A10ᶜ⁷⁹⁶T cells are available, subjects will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine, followed by the T cell infusion. The purpose of this study is to test the safety of genetically changed T cells and find out what effects, if any, they have in subjects with lung cancer. The study will evaluate three different cell dose levels in order to find out the target cell dose. Once the target cell dose is determined, additional subjects will be enrolled to further test the safety and effects at this cell dose.

Subjects will be seen frequently by the Study Physician right after receiving their T cells back and up to first 6 months. After that, subjects will be seen every three months. Subjects will be seen every 6 months by their Study Physician for the first 5 years after the T cell infusion. If the T cells are found in the blood at five years, then the subjects will continue to be seen once a year until the T cells are no longer found in the blood for a maximum of 15 years. If the T cells are no longer found in the blood at 5 years, then the subject will be contacted by the Study Physician for the next 10 years. Subjects who have a confirmed response (or have stable disease for >4 months) but subsequent disease progression following the initial infusion and whose tumor continues to express the appropriate antigen target may be eligible for a second infusion. All subjects, completing or withdrawing from the Interventional Phase of the study, will enter a 15-year long-term follow-up phase for observation of delayed adverse events, All subjects will continue to be followed for overall survival during the long-term follow-up phase.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Carcinoma Biological: Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Actual Study Start Date : November 2015
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : April 2034

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T Biological: Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T

Primary Outcome Measures :
  1. Number of subjects with dose-limiting toxicity (DLT) and adverse events (AE), including serious adverse events (SAE) [ Time Frame: 24 months ]
    Determine if treatment with autologous genetically modified T cells, (MAGE A10ᶜ⁷⁹⁶T ) is safe and tolerable through assessment of DLTs, AEs, including SAEs; laboratory assessments, including chemistry, hematology, and coagulation; cardiac and pulmonary assessments, including ECG and pulmonary function (pulse oximetry).

Secondary Outcome Measures :
  1. Proportion of subjects with a confirmed Complete Response (CR) or Partial Response (PR) [ Time Frame: 24 months ]
    Evaluation of the efficacy of the treatment by assessment of the Overall Response Rate according to RECIST v1.1

  2. Interval between the date of first T cell infusion dose and first documented evidence of CR or PR [ Time Frame: 24 months ]
    Evaluation of the efficacy of the treatment by assessment of time to first response

  3. Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause [ Time Frame: 24 months ]
    Evaluation of the efficacy of the treatment by assessment of duration of response

  4. Interval between the date of first documented evidence of SD until first documented disease progression or death due to any cause [ Time Frame: 24 months ]
    Evaluation of the efficacy of the treatment by assessment of duration of stable disease

  5. Interval between the date of first T cell infusion and the earliest date of disease progression or death due to any cause [ Time Frame: 24 months ]
    Evaluation of the efficacy of the treatment by assessment of progression-free survival

  6. Interval between the date of first T cell infusion and date of disease progression or death due to any cause [ Time Frame: 24 months ]
    Evaluation of the efficacy of the treatment by assessment of overall survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  1. Subject has histologically or cytologically confirmed diagnosis of advanced non-small cell lung cancer (stage IIIB or IV) or recurrent disease
  2. Subject has received at least one line of prior therapy
  3. Subjects with known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase receptor (ALK) or ROS1 gene rearrangements must have failed (progressive disease or unacceptable toxicity) at least one prior EGFR or ALK or ROS1 tyrosine kinase inhibitor, respectively. Subject may have received PD-1 or PDL-1 inhibitors and or chemotherapy. There is no limit on lines of prior anti-cancer therapy (a washout period applies for recent anti-cancer treatments).
  4. Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion.
  5. Subject is HLA-A*02:01 or HLA-A*02:06 positive.
  6. Subject's tumor (either an archival specimen or a fresh biopsy if archival tissue is unavailable) has been pathologically reviewed by a designated central laboratory confirming MAGE-A10 expression.
  7. Subject has an ECOG Performance Status 0-1 and anticipated life expectancy >6 months prior to apheresis and >3 months prior to lymphodepletion.
  8. Subject is ≥18 years of age
  9. Adequate organ function

Key Exclusion Criteria:

  1. Subject is HLA-A*02:05, HLA-B*15:01 and/or HLA-B*46:01 positive.
  2. History of chronic or recurrent (within the last year prior to enrollment) severe autoimmune or active immune-mediated disease requiring steroids or other immunosuppressive treatments.
  3. Subject has symptomatic CNS metastases. Subjects with prior history of symptomatic CNS metastasis must have received treatment and be neurologically stable for at least 1 month prior to leukapheresis and lymphodepletion.
  4. Active malignancy besides NSCLC within 3 years prior to screening.
  5. Uncontrolled intercurrent illness including, but not limited to:

    • Ongoing or active infection;
    • Clinically significant cardiac disease
    • Inadequate pulmonary function
    • Interstitial lung disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02592577

Layout table for location contacts
Contact: Ben Creelan, MD, MS 813-745-3328
Contact: Matt Taddeo

Layout table for location information
United States, California
City of Hope Recruiting
Duarte, California, United States, 91010
Contact: Cara Nolan    626-256-4673 ext 32341   
Principal Investigator: Karen Reckamp, MD         
Stanford Cancer Center Recruiting
Palo Alto, California, United States, 94304
Contact: Jordan S Preiss, BA    650-723-1002   
Principal Investigator: Joel W Neal, MD PhD         
United States, Florida
University of Miami Sylvester Comprehensive Cancer Center Recruiting
Miami, Florida, United States, 33136
Contact: Elsie Medina    305-243-0363   
Principal Investigator: Raja Mudad, M.D.         
H. Lee Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Contact: Caitlyn Ward    813-745-1344   
Principal Investigator: Ben Creelan, MD, MS         
United States, Georgia
Winship Cancer Institute of Emory University Recruiting
Atlanta, Georgia, United States, 30322
Contact: Tolu Adewuya    404-778-5157   
Principal Investigator: Taofeek K Owonikoko, MD, PhD         
United States, Indiana
Indiana University Simon Cancer Center Recruiting
Indianapolis, Indiana, United States, 46033
Contact: Margaret M Uhrich, RN    317-274-4505   
Principal Investigator: Shadia I Jalal, MD         
United States, Maryland
University of Maryland, Greenebaum Cancer Center Recruiting
Baltimore, Maryland, United States, 21157
Contact: Noemi Cortes    410-328-6465   
Contact: Maha Khalil   
Principal Investigator: Christian Rolfo, MD         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Kevin Lindell   
Principal Investigator: Justin F Gainor, M.D.         
United States, Missouri
Washington University, School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Usha Rawat    314-286-2098   
Principal Investigator: Ramaswamy Govindan, MD         
United States, North Carolina
Duke University Medical Center, Duke Cancer Institute Recruiting
Durham, North Carolina, United States, 27710
Contact: Shawna Savage, RN, BSN    919-668-1462   
Principal Investigator: Jeffrey M Clarke, MD         
United States, Ohio
Ohio State University Wexner Medical Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Catherine Schweitzer    614-685-5414   
Principal Investigator: Kai He, MD         
United States, Pennsylvania
Fox Chase Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19111
Contact: Elisabeth Giraud   
Contact: Danielle Thor   
Principal Investigator: Martin Edelman, MD         
United States, Tennessee
Tennessee Oncology- Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Contact    615-329-7400   
Principal Investigator: Melissa Johnson, MD         
United States, Texas
The University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Debora Clay    713-745-0294   
Contact: Sara Nasser   
Principal Investigator: George Blumenschein, MD         
Canada, Ontario
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada, M5G1X6
Contact: Penelope Bradbury, MD    416-946-4501 ext 3544   
Contact: Minge Xu   
Principal Investigator: Penelope Bradbury, MD         
Hospital Universitario Fundación Jiménez Díaz Recruiting
Madrid, Spain, 28040
Contact: Adriana Armellini    91 550 48 00 ext 2486   
Contact: Alberto Urbano   
Principal Investigator: Victor Moreno, MD         
Hospital Universitario 12 Octubre Avda. de Córdoba s/n Recruiting
Madrid, Spain, 28041
Contact: Ana Cortijo    +34 91 390 8923   
Contact: Carlos Gonzalez         
Principal Investigator: Luis Paz-Ares Rodríguez, MD         
United Kingdom
University College Hospital Macmillan Cancer Centre Recruiting
London, United Kingdom, WC1E 6AG
Contact: Krishna Patel    +44 7960 779 970   
Principal Investigator: Martin D Forster, MBBS, FRCP, PhD         
The Christie NHS Foundation Trust Recruiting
Manchester, United Kingdom, M20 4BX
Contact: Shweta Vyas    +44 (0) 161 918 2323   
Contact: Kate Armitage    +44 (0) 161 918 7887   
Principal Investigator: Fiona Thistlethwaite, MD         
Sponsors and Collaborators
Layout table for investigator information
Study Chair: Ben Creelan, MD, MS H. Lee Moffitt Cancer Center

Layout table for additonal information
Responsible Party: Adaptimmune Identifier: NCT02592577     History of Changes
Other Study ID Numbers: ADP 0022-003
First Posted: October 30, 2015    Key Record Dates
Last Update Posted: February 6, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Adaptimmune:
Previously Treated
Cell Therapy
T Cell Therapy
T Cell Receptor
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms